Showing results (71-80 of 82) with videos related to
Sort By:
Pageof 9
Molecular Pharmaceutics|April 21, 2025
Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast CancerMd Jashim Uddin, Justin Han-Je Lo, Mukesh K Gupta, et al.Biomaterials|August 31, 2024
Intravascular delivery of an MK2 inhibitory peptide to prevent restenosis after angioplastyJ William Tierney, R Paolo Francisco, Fang Yu, et al.Biorxiv : the Preprint Server for Biology|June 19, 2023
Albumin-binding RNAi Conjugate for Carrier Free Treatment of ArthritisJuan M Colazo, Ella N Hoogenboezem, Megan C Keech, et al.JCI Insight|July 8, 2020
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBCDerek A Franklin, Joe T Sharick, Paula I Ericsson-Gonzalez, et al.Nature Biomedical Engineering|May 16, 2025
siRNA conjugate with high albumin affinity and degradation resistance for delivery and treatment of arthritis in mice and guinea pigsJuan M Colazo, Megan C Keech, Veeraj Shah, et al.Biorxiv : the Preprint Server for Biology|February 24, 2023
Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer TherapyElla N Hoogenboezem, Shrusti S Patel, Ashley B Cavnar, et al.Science Translational Medicine|April 15, 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceJustin M Balko, Luis J Schwarz, Na Luo, et al.Nature Communications|February 21, 2024
Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapyElla N Hoogenboezem, Shrusti S Patel, Justin H Lo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2015
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsSherene Loi, Sathana Dushyanthen, Paul A Beavis, et al.Journal of Medicinal Chemistry|April 2, 2019
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human CancerTaekyu Lee, Plamen P Christov, Subrata Shaw, et al.Pageof 9